Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments with immune checkpoint inhibitors and hematopoietic stem cell therapies alone are ineffective for many cancers and infectious diseases, and there is a need for a synergistic approach to overcome resistance to immune checkpoint blockade.
Innovation Solution
Combining hematopoietic stem cell transfer with immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, or anti-VISTA antibodies, to enhance T cell activation and persistence in the tumor microenvironment, promoting long-term regression of checkpoint inhibitor-resistant cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors are used alone, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient for many cancers
Solution Approach 1:
The patent combines immune checkpoint inhibitors with hematopoietic stem cell transplantation to create a synergistic therapy. The immune checkpoint inhibitor (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) is administered concurrently with or after HSC transfer, merging two previously separate treatments into a unified therapeutic approach that overcomes resistance mechanisms while maintaining manageable complexity through coordinated scheduling and monitoring protocols.
2Reliability
If hematopoietic stem cell transplantation is used alone, then cancer regression can be achieved in some cases, but the treatment is ineffective for checkpoint inhibitor-resistant cancers
Solution Approach 1:
The combined therapy achieves multi-functionality by addressing multiple resistance mechanisms simultaneously. The immune checkpoint inhibitor blocks inhibitory signals from cancer cells, while HSC transplantation provides immunocompetent cells capable of recognizing and destroying residual tumor cells. This universal approach works across different cancer types and resistance profiles, making the treatment adaptable to various clinical scenarios including checkpoint inhibitor-resistant cancers.
3Reliability
If combination therapy with HSC transfer and immune checkpoint inhibitors is used, then synergistic effect and long-term regression are achieved, but treatment complexity increases
Solution Approach 1:
The protocol employs preliminary action by administering HSC transfer before or concurrently with the immune checkpoint inhibitor, preparing the patient's immune system in advance. The HSCs are transferred to reconstitute the hematopoietic system, and then the immune checkpoint inhibitor is given to activate T cells. This sequencing ensures that immunocompetent cells are available to respond to the checkpoint blockade, maximizing synergistic effect while managing complexity through predefined timing protocols.
Data Source
AI summary
The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.